DETAILS, FICTION AND CLINICAL EFFECTIVENESS OF ABBV-744 IN AML PATIENTS

In Phase A, members will obtain distinct doses and schedules of oral ABBV-744 tablet to recognize Protected dosing program. Supplemental members is going to be enrolled on the identified monotherapy dosign program. In Phase B, members will receive oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, members will rec